Ronan O'Hagan

Ronan O'Hagan has a strong background in the biotech and pharmaceutical industry. Ronan is currently serving as the President & CEO of Biotech NewCo since March 2022. Prior to that, they were the Chief Scientific Officer at Apricity Health starting in September 2021. From June 2018 to August 2021, Ronan held the position of Chief Scientific Officer at Xilio Therapeutics, Inc. Before that, they worked at Merck in various roles including Executive Director, Oncology Discovery, Oncology Discovery Lead, Director, Oncology Discovery, and Oncology Target Identification and Validation Lead from 2011 to 2018. Ronan started their career as an Associate Director, Target Biology at AVEO Pharmaceuticals, Inc. from May 2002 to November 2011. Ronan's earlier experience includes research fellowships at Dana-Farber Cancer Institute and Harvard Medical School from July 1998 to April 2002.

Ronan O'Hagan began their education journey in 1988 when they enrolled at the University of Manitoba. Ronan attended the University of Manitoba for four years, completing their studies in 1992. However, no specific degree or field of study is provided for this period.

In 1992, after finishing their time at the University of Manitoba, Ronan O'Hagan moved on to attend McMaster University. Ronan studied at McMaster for six years, until 1998. However, similar to their time at the University of Manitoba, no specific degree or field of study information is given.

In terms of additional certifications, Ronan O'Hagan obtained a certification from VC University Online in December 2021. The certification was granted by VC University.